These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31070007)

  • 1. Circulating complement-1q tumor necrosis factor-α-related protein isoform 5 levels are low in type 2 diabetes patients and reduced by dapagliflozin.
    Zhang C; Luo Y; Liu R; Li X; Yang M; Zhang Y; Li L; Mou H; Guo L; Li J; Liu H; Yang G; Zhang X
    J Diabetes Investig; 2020 Jan; 11(1):88-95. PubMed ID: 31070007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of serum C1q-tumour necrosis factor-related protein 5 levels with metabolic parameters and carotid intima-media thickness in newly diagnosed type 2 diabetes mellitus patients.
    Uçar İMB; Çalan M; Tatar E; Chousein R; Fenercioğlu ÖE; Bozkaya G; Yüksel A
    Hormones (Athens); 2020 Dec; 19(4):559-564. PubMed ID: 32594414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relation between HOMA-IR and insulin sensitivity index determined by hyperinsulinemic-euglycemic clamp analysis during treatment with a sodium-glucose cotransporter 2 inhibitor.
    So A; Sakaguchi K; Okada Y; Morita Y; Yamada T; Miura H; Otowa-Suematsu N; Nakamura T; Komada H; Hirota Y; Tamori Y; Ogawa W
    Endocr J; 2020 May; 67(5):501-507. PubMed ID: 32023587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid profile in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective lipid profile from single center.
    Calapkulu M; Cander S; Gul OO; Ersoy C
    Diabetes Metab Syndr; 2019; 13(2):1031-1034. PubMed ID: 31336439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
    Luo M; Kong X; Wang H; Zhai X; Cai T; Ding B; Hu Y; Jing T; Su X; Li H; Ma J
    J Diabetes Res; 2020; 2020():6666403. PubMed ID: 33299890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myonectin Predicts the Development of Type 2 Diabetes.
    Li K; Liao X; Wang K; Mi Q; Zhang T; Jia Y; Xu X; Luo X; Zhang C; Liu H; Zhen H; Li L; Yang G
    J Clin Endocrinol Metab; 2018 Jan; 103(1):139-147. PubMed ID: 29161407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.
    Kinoshita T; Shimoda M; Nakashima K; Fushimi Y; Hirata Y; Tanabe A; Tatsumi F; Hirukawa H; Sanada J; Kohara K; Irie S; Kimura T; Nakamura Y; Nishioka M; Obata A; Nakanishi S; Mune T; Kaku K; Kaneto H
    J Diabetes Investig; 2020 Nov; 11(6):1612-1622. PubMed ID: 32329963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus.
    Kohlmorgen C; Gerfer S; Feldmann K; Twarock S; Hartwig S; Lehr S; Klier M; Krüger I; Helten C; Keul P; Kahl S; Polzin A; Elvers M; Flögel U; Kelm M; Levkau B; Roden M; Fischer JW; Grandoch M
    Diabetologia; 2021 Aug; 64(8):1834-1849. PubMed ID: 34131781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial.
    Bonora BM; Vigili de Kreutzenberg S; Avogaro A; Fadini GP
    Cardiovasc Diabetol; 2019 Aug; 18(1):106. PubMed ID: 31412874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Dapaglifozin and Liraglutide in Patients with Poorly Controlled Type 2 Diabetes Mellitus: a 24-week, Open, Double-centered, Head to Head Trial.
    Jiang J; Lin L; Chen P
    Endocr Metab Immune Disord Drug Targets; 2021; 21(7):1366-1374. PubMed ID: 32875989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study.
    Terauchi Y; Fujiwara H; Kurihara Y; Suganami H; Tamura M; Senda M; Gunji R; Kaku K
    J Diabetes Investig; 2019 Nov; 10(6):1518-1526. PubMed ID: 31033218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of dapagliflozin treatment on epicardial adipose tissue volume.
    Sato T; Aizawa Y; Yuasa S; Kishi S; Fuse K; Fujita S; Ikeda Y; Kitazawa H; Takahashi M; Sato M; Okabe M
    Cardiovasc Diabetol; 2018 Jan; 17(1):6. PubMed ID: 29301516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison betweeen dapagliflozin add-on therapy and insulin dose escalation in patients with uncontrolled type 2 diabetes treated with insulin: DVI study.
    Shin Y; Choi H; Lim S
    Diabetes Res Clin Pract; 2021 May; 175():108843. PubMed ID: 33933498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial.
    Yamakage H; Tanaka M; Inoue T; Odori S; Kusakabe T; Satoh-Asahara N
    J Diabetes Investig; 2020 May; 11(3):653-661. PubMed ID: 31721467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anthropometric outcomes in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective glycemic control from single center.
    Calapkulu M; Cander S; Gul OO; Ersoy C
    Diabetes Metab Syndr; 2019; 13(1):284-288. PubMed ID: 30641713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of sodium glucose cotransporter type 2 inhibitors dapagliflozin on diabetic nephropathy in rats; Inflammation, angiogenesis and apoptosis.
    Elkazzaz SK; Khodeer DM; El Fayoumi HM; Moustafa YM
    Life Sci; 2021 Sep; 280():119018. PubMed ID: 33549594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor.
    Feng X; Gu Q; Gao G; Yuan L; Li Q; Zhang Y
    Ann Endocrinol (Paris); 2020 Oct; 81(5):476-481. PubMed ID: 32822653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Dapagliflozin Adjunct to Insulin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes: A Randomized, Controlled, Open-Labeled Trial.
    Jiang LL; Zhang P; Liu BL; Yan RN; Ye L; Ma JH; Li FF
    Biomed Res Int; 2021; 2021():6618257. PubMed ID: 34497852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
    Bekki M; Tahara N; Tahara A; Igata S; Honda A; Sugiyama Y; Nakamura T; Sun J; Kumashiro Y; Matsui T; Fukumoto Y; Yamagishi SI
    Curr Vasc Pharmacol; 2019; 17(4):411-420. PubMed ID: 29766812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.